Add this result to my export selection Controlled drugs and drug dependence | Medicines guidance Source: British National Formulary - BNF (Add filter) 21 January 2021 buprenorphine , gabapentin , mazindol, meprobamate, midazolam , pentazocine, phentermine, pregabalin, temazepam , and tramadol... Type: Prescribing and Technical Information (Add filter)
Add this result to my export selection Controlled drugs and drug dependence | Medicines guidance Source: British National Formulary for Children - BNFc (Add filter) 21 January 2021 buprenorphine , gabapentin , mazindol, meprobamate, midazolam , pentazocine, phentermine, pregabalin, temazepam , and tramadol... Type: Prescribing and Technical Information (Add filter)
Add this result to my export selection Long‐term effects of weight‐reducing drugs in people with hypertension Source: Cochrane Database of Systematic Reviews (Add filter) 17 January 2021 blood pressure and a mean age of 46 to 55 years; one trial comparing phentermine/topiramate to placebo, involving 1305 participants with... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0 Published by Society of Nuclear Medicine, 09 May 2020 This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging... Read Summary Type: Guidance (Add filter)
Add this result to my export selection Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial Published by The Lancet, 18 December 2019 RCT (n=119) found that fenfluramine 0.7 & 0.2mg/kg showed a 62.3% &32.4% greater reduction in monthly convulsive seizure frequency vs placebo (p<0.0001 & p=0.0209 for difference respectively). SPS comment Type: Primary Research (Add filter)
Add this result to my export selection Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Source: PubMed (Add filter) Published by Expert review of clinical pharmacology, 26 November 2019 weight with orlistat (N=10,435; ∆ -3.07 Kg, 95% CI, -3.76 to -2.37), phentermine plus topiramate (N=2985; ∆ -9.77 Kg; 95% CI, -11.73 to... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis. Source: PubMed (Add filter) Published by The Journal of clinical endocrinology and metabolism, 31 July 2019 enzyme inhibitors, angiotensin II receptor blockers, metformin, orlistat, phentermine-topiramate and pioglitazone significantly reduced... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial Source: Cochrane Central Register of Controlled Trials (Add filter) Published by Metabolism: clinical and experimental, 01 July 2019 Background: This pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who... Read Summary Type: Primary Research (Add filter)
Add this result to my export selection The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. Source: PubMed (Add filter) Published by Journal of drug assessment, 01 January 2019 observed slightly greater weight loss with the use of topiramate and phentermine as a monotherapy compared to other weight loss... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Care of women with obesity in pregnancy: green-top guideline no 72 Published by British Journal of Obstetrics and Gynaecology, 22 November 2018 Obesity is one of the most common health risk factors in pregnancy (latest figures show 22% of pregnant women in England are obese). This guidance includes recommendations on how to manage weight... SPS comment Type: Guidance (Add filter)
Add this result to my export selection The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea : An Official American Thoracic Society Clinical Practice Guideline (PDF) Published by American Thoracic Society, 15 September 2018 The purpose of this guideline is to provide evidence-based recommendations for the management of overweight/obesity in patients with obstructive sleep apnea (OSA). Read Summary Type: Guidance (Add filter)
Add this result to my export selection ACR-ACNM Practice Parameter for the Performance of Dopamine (DaT) Transporter Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders (PDF) Source: American College of Radiology (Add filter) 18 December 2017 d-amphetamine, methamphetamine, methylphenidate : CNS stimulants: ephedrine, phentermine Drugs that do not increase or decrease striatal... Type: Guidance (Add filter)
Add this result to my export selection Obesity: Scenario: Management Source: Clinical Knowledge Summaries - CKS (Add filter) 01 December 2017 Approach the subject of weight carefully because people who are overweight or obese may be sensitive about discussing it, or feel that their presenting problem is... Type: Guidance (Add filter)
Add this result to my export selection Drug misuse and dependence: UK guidelines on clinical management (PDF) Source: Department of Health (Add filter) Published by Department of Health, 17 July 2017 The 2017 update offers guidance on; prison-based treatment; new psychoactive substances and club drugs; mental health co-morbidity; misuse of prescribed and over-the-counter medicines; stopping... SPS comment Type: Guidance (Add filter)
Add this result to my export selection Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial Published by Diabetes Care, 14 March 2017 This RCT (n=355) reports an absolute reduction in weight of 0.6kg with placebo, 1.9kg with canagliflozin (C), 4.1kg with phentermine (P) and 7.3kg with combination C+P over 26-weeks. C+P also had... SPS comment Type: Primary Research (Add filter)
Add this result to my export selection 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Published by The Lancet, 23 February 2017 By week 160, 26 (2%) of 1472 on liraglutide (LG) vs. 46 (6%) of 738 on placebo were diagnosed with diabetes (DB) while on treatment. Time to onset of DB was 2.7 times longer with LG vs. placebo (HR... SPS comment Type: Primary Research (Add filter)
Add this result to my export selection General practice management of type 2 diabetes 2016–18 (PDF) Published by Royal Australian College of General Practitioners;Diabetes Australia, 01 September 2016 These Australian guidelines have been designed to provide pragmatic, evidence-based recommendations for use in general practice and adopt the most recent recommendations from organisations... Read Summary Type: Guidance (Add filter)
Add this result to my export selection The safer management of controlled drugs: Annual report 2015 (PDF) Source: Care Quality Commission - CQC (Add filter) Published by Care Quality Commission, 15 July 2016 In this report, the CQC makes 3 recommendations to strengthen existing arrangements for reporting and sharing of controlled drug concerns across England. It showcases local and national initiatives... Read Summary
Add this result to my export selection Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis Published by Journal of the American Medical Association, 15 June 2016 Review of 28 RCTs found in overweight/obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate (PT), and liraglutide were associated with achieving at least 5% weight loss at... SPS comment Type: Systematic Reviews (Add filter)
Add this result to my export selection Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis Source: PubMed (Add filter) Published by Jama, 14 June 2016 long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis Published by International Journal of Clinical Practice, 06 June 2016 In this review of 9 studies (6 RCTs) a meta-analysis of 3 of the RCTs (n=121) found that orlistat and metformin had similar positive effects on BMI, testosterone and insulin in overweight/obese PCOS... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers Published by British Journal of Clinical Pharmacology, 07 April 2016 Raynaud’s phenomenon (RP) is likely an underestimated adverse drug event, with limited available evidence regarding its prevalence. This review identified 12 classes of drugs responsible for RP. Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Long‐term effects of weight‐reducing drugs in people with hypertension Source: Cochrane Database of Systematic Reviews (Add filter) 02 March 2016 additional study of phentermine/topiramate, bringing the total number of studies to nine that compare orlistat, sibutramine, or... Type: Systematic Reviews (Add filter)
Add this result to my export selection A Comparison of New Pharmacological Agents for the Treatment of Obesity Source: PubMed (Add filter) Published by The Annals Of Pharmacotherapy, 17 February 2016 between these agents at this point, which limits comparisons across agents. Phentermine/topiramate ER appeared to have the best overall... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection ASGE position statement on endoscopic bariatric therapies in clinical practice (PDF) Source: American Society for Gastrointestinal Endoscopy (Add filter) Published by American Society for Gastrointestinal Endoscopy, 01 November 2015 The American Society for Gastrointestinal Endoscopy (ASGE), as well as a number of federal agencies and medical societies, recognizes obesity as a disease requiring primary therapy.1 In 2011, the... Read Summary Type: Guidance (Add filter)
Add this result to my export selection Heritable Pulmonary Arterial Hypertension. Source: GeneReviews (Add filter) Published by GeneReviews®, 11 June 2015 Agents/circumstances to avoid: Appetite suppressants, such as fenfluramine/phentermine, dexfenfluramine, and amfepramone... Type: Evidence Summaries (Add filter)
Add this result to my export selection Smoking, nutrition, alcohol, physical activity (SNAP): a population health guide to behavioural risk factors in general practice 2nd edition (PDF) Published by Royal Australian College of General Practitioners, 18 March 2015 This Australian guide has been designed to assist general practitioners (GPs) and practice staff to work with patients on the lifestyle risk factors of smoking, nutrition, alcohol and physical... Read Summary Type: Guidance (Add filter)
Add this result to my export selection Cost-effectiveness analysis of qsymia for weight loss Source: NHS Economic Evaluation Database - NHS EED (Add filter) 31 July 2014 Anti-Obesity Agents; Appetite Depressants; Costs and Cost Analysis; Humans; Phentermine AccessionNumber 22014027855 Date bibliographic... Read Summary Type: Economic Evaluations (Add filter)
Add this result to my export selection Drug use, impaired driving and traffic accidents (PDF) Source: European Monitoring Centre for Drugs and Drug Addiction (Add filter) 01 June 2014 namely amphetamine, methamphetamine, MDMA, ephedrine, pseudoephedrine, phentermine and cocaine. There was no significant association... Type: Evidence Summaries (Add filter)
Add this result to my export selection Addiction potential of phentermine prescribed during long-term treatment of obesity Source: Medicines Management Collection (Add filter) Published by International Journal of Obesity, 08 May 2014 Objective: To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or... Read Summary Type: Primary Research (Add filter)
Add this result to my export selection National report 2013: France (PDF) Source: European Monitoring Centre for Drugs and Drug Addiction (Add filter) 01 May 2014 galenical forms of phentermine and cathinones on the narcotics list: Order of 14 February 201257 on the classification of all... Type: Evidence Summaries (Add filter)
Add this result to my export selection Drug use, impaired driving and traffic accidents (2nd edition) (PDF) Source: European Monitoring Centre for Drugs and Drug Addiction (Add filter) Published by European Monitoring Centre for Drugs and Drug Addiction, 01 May 2014 Insights series This literature review provides a comprehensive report on the relationship between drug use, impaired driving and traffic accidents. It describes methodological issues, presents... Read Summary Type: Primary Research (Add filter)
Add this result to my export selection American Society of Interventional Pain Physicians (ASIPP) : guidelines for responsible opioid prescribing in chronic non-cancer pain : part 2 - guidance (PDF) Published by American Society of Interventional Pain Physicians, 01 January 2014 Background: Opioid abuse has continued to increase at an alarming rate since the 1990s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement... Read Summary Type: Guidance (Add filter)
Add this result to my export selection Use of prescription antiobesity drugs in the United States Source: Medicines Management Collection (Add filter) Published by Pharmacotherapy, 05 December 2013 approximately 2.74 million patients used antiobesity drugs, predominantly phentermine (2.43 million patients). The use of... Read Summary Type: Primary Research (Add filter)
Add this result to my export selection Psychoactive substance use by truck drivers : a systematic review Published by BMJ Group, 21 October 2013 Girotto,E., Mesas,A.E., de Andrade,S.M. et al (2013) Psychoactive substance use by truck drivers: a systematic review. Occupational and Environmental Medicine. E-pub ahead of print. This... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Human medicine European public assessment report (EPAR): Qsiva Source: European Medicines Agency - EMA (Add filter) 13 June 2013 "EMA_News" } RSS phentermine / topiramate Table of contents Type: Prescribing and Technical Information (Add filter)
Add this result to my export selection National report 2012: France (PDF) Source: European Monitoring Centre for Drugs and Drug Addiction (Add filter) 01 June 2013 of dangerous substances and to classify all pharmaceutical forms of "phentermine" as narcotics: : Decree of 25 July 201152, which... Type: Evidence Summaries (Add filter)
Add this result to my export selection National report 2012: Italy (PDF) Source: European Monitoring Centre for Drugs and Drug Addiction (Add filter) 01 June 2013 additions, moving the drugs Amfepramone (diethylpropion), Phendimetrazine, Phentermine and Mazindol into Table I." Ministerial Decree of... Type: Evidence Summaries (Add filter)
Add this result to my export selection Qsymia (phentermine/topiramate; Vivus Inc.) for obesity management Source: Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA (Add filter) Published by Centre for Reviews and Dissemination, 23 April 2013 Qsymia (phentermine/topiramate; Vivus Inc.) for obesity management Record Status Read Summary Type: Health Technology Assessments (Add filter)
Add this result to my export selection Mortality among people who inject drugs : a systematic review and meta-analysis Source: World Health Organization (Add filter) Published by World Health Organization (WHO), 01 February 2013 Mathers BM, Degenhardt L, Bucello C, et al. (2013) Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization 91: 102-213 This... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection Mortality among people who inject drugs : a systematic review and meta-analysis Source: World Health Organization (Add filter) Published by World Health Organization (WHO), 01 February 2013 Mathers BM, Degenhardt L, Bucello C et al. (2013) Mortality among people who inject drugs: A systematic review and meta-analysis. Bulletin of the World Health Organization 91: 102-23 This... Read Summary Type: Systematic Reviews (Add filter)
Add this result to my export selection National report 2011: Hungary (PDF) Source: European Monitoring Centre for Drugs and Drug Addiction (Add filter) 01 November 2012 2010 were the following: p-fluoroamphetamine, trimethoxyamphetamine, phentermine. In 2010 a total of 18,411 tablets containing illicit... Type: Evidence Summaries (Add filter)
Add this result to my export selection Cardiovascular risk assessment in the development of new drugs for obesity Source: Medicines Management Collection (Add filter) Published by Journal of the American Medical Association, 19 September 2012 from 3% for lorcaserin (approved in Jun 2012) to 9% for phentermine/topiramate. Cardiovascular safety information about... Read Summary Type: Primary Research (Add filter)
Add this result to my export selection Human enhancement drugs the emerging challenges to public health (PDF) Source: Public Health Institute, Liverpool John Moores University (Add filter) Published by Public Health Institute, Liverpool John Moores University, 01 August 2012 (2012) Human enhancement drugs the emerging challenges to public health. : Public health faces a new kind of drug problem with the growing prevalence of so–called ‘enhancement drugs’ that have... Read Summary Type: Evidence Summaries (Add filter)
Add this result to my export selection Human Enhancement Drugs – The Emerging Challenges to Public Health (PDF) Source: Public Health Institute, Liverpool John Moores University (Add filter) 11 April 2012 Public health faces a new kind of drug problem with the growing prevalence of so-called ‘enhancement drugs’ that have the potential to improve human attributes and abilities. The... Type: Primary Research (Add filter)
Add this result to my export selection SNM practice guideline for dopamine transporter imaging with 123 I-Ioflupane SPECT 1.0 (PDF) Published by Society of Nuclear Medicine, 08 December 2011 The purpose of this information is to assist health care professionals in performing, interpreting, and reporting the results of DaT imaging with 123 I-ioflupane SPECT. Read Summary Type: Guidance (Add filter)
Add this result to my export selection Phentermine/topiramate (Qnexa) for weight loss and maintenance of weight loss Source: Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA (Add filter) Published by Centre for Reviews and Dissemination, 31 August 2011 Phentermine/topiramate (Qnexa) for weight loss and maintenance of weight loss National Horizon Scanning Centre Read Summary Type: Health Technology Assessments (Add filter)
Add this result to my export selection Phentermine/topiramate (Qnexa) for weight loss and maintenance of weight loss Source: NIHR Innovation Observatory (Add filter) 01 April 2011 Phentermine/topiramate (Qnexa, VI-0521) is an oral low-dose combination of immediate-release phentermine and prolonged-release topiramate. Phentermine is a US licensed appetite suppressant, while... Type: Horizon Scanning (Add filter)
Add this result to my export selection Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus Source: Cochrane Database of Systematic Reviews (Add filter) 24 January 2005 was noted in three studies of mazindol, one of phenmetrazine, two of phentermine. No studies were identified that fit inclusion criteria... Type: Systematic Reviews (Add filter)
Add this result to my export selection Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies Source: Database of Abstracts of Reviews of Effects - DARE (Add filter) 31 October 2004 fenfluramine or dexfenfluramine, either alone or in combination with phentermine, were eligible for inclusion. Participants included in... Type: Systematic Reviews (Add filter)
